Market Overview

ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting


(NASDAQ:ICLR), a global provider of drug
development solutions and services to the pharmaceutical, biotechnology
and medical device industries, today announced that all resolutions at
the Annual General Meeting of the Company (AGM) held on July 25, 2017
(which resolutions had all been recommended by the Board) were all duly
passed by shareholders. These resolutions were set out in the Notice of
the AGM sent to shareholders dated June 23, 2017 and are available on
the ICON
plc website

The final results of the voting are as follows:

1.1 To re-elect Prof. Dermot Kelleher 45,317,741 44,238,348 1,032,397 46,996
1.2 To re-elect Prof. Hugh Brady 45,317,741 44,918,234 352,536 46,971
1.3 To re-elect Ms. Mary Pendergast 45,317,741 44,917,849 351,464 48,428
1.4 To re-elect Mr. Ronan Murphy 45,317,741 44,630,167 640,062 47,512
2 To receive accounts and reports 45,317,741 45,142,850 3,142 171,749
3 To authorise the fixing of the auditors' remuneration 45,317,741 41,762,920 3,548,967 5,854
4 To authorise the Company to allot shares 45,317,741 44,310,484 865,120 142,137
5** To disapply pre-emption rights 45,317,741 44,917,093 238,190 162,458
6** To disapply pre-emption rights for funding capital investment or
45,317,741 44,918,013 237,460 162,268
7** To authorise the Company to make market purchases of shares 45,317,741 45,177,034 9,283 131,424
8** To authorise the price range at which the Company can reissue shares
it holds as treasury shares
45,317,741 44,962,079 121,491 234,171

** Special Resolution. All resolutions are ordinary resolutions unless
otherwise stated.

This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 84 locations in 38 countries and
has approximately 12,300 employees. Further information is available at

Source: ICON plc


View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at